Many growth stocks and exchange-traded funds (ETFs) are currently changing hands around 52-week or even multi-year lows and the impending earnings season could bring more...
When we’re faced with a situation like today’s, with inflation and interest rates on a tear, we want dividends that keep us ahead of rising prices while hedging us...
Executive Summary Shareholder meetings and conferences ramp up after a busy summer and ahead of the next earnings season The Delta variant forced many companies to quickly switch...
Roche RHHBY (OTC:RHHBY) announced that the FDA has approved the label expansion of asthma drug, Xolair. The agency approved the company’s supplemental Biologics License...
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. REGN announced first data from a descriptive analysis of a seamless phase I/II/III study, evaluating its antibody cocktail candidate,...
Bristol Myers (NYSE:BMY) Squibb BMY announced that the phase III study, CheckMate-274, on immuno-oncology drug, evaluating Opdivo, after surgery in patients with high-risk,...
Friday, September 18, 2020The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks,...
Bayer AG (DE:BAYGN)’s BAYRY second-quarter 2020 core earnings per share of 44 cents per American Depositary Receipt ("ADR") decreased from 46 cents reported in the year-ago...
Share price of Immunomedics (NASDAQ:IMMU) Inc. IMMU has surged 77.4% year to date compared with the industry’s growth of 11%. It has been an eventful year so far for the...
Novartis AG NVS announced that the FDA has approved a label update for ophthalmology drug, Beovu (brolucizumab), to include additional safety information regarding retinal...
18 per and 4% dividend starts looking good. Long hold and nice life investment in one of Europe best companies in a non hype sector
0
What happened today?
1
It is a buy at 266
2
When ist best time to buy?
0
SP suffering since May 2022 due to decline in COVID vaccines.
0
macd indicators showing a nice jump coming, keeping my fingers crossed during these dark times
0
What happened today?
0
The SKYSCRAPER-01 study evaluating tiragolumab plus Tecentriq did not meet its co-primary endpoint of progression-free survival
0
Today only this info about Roche
0
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
5
hello to Marinopoulos Pharma company .!
0
Trades ex dividend!!
0
Currently near to Fibo 61.8 levels, a great company to buy IMO.